Wikio - Vertex Pharmaceuticals

Vertex Pharmaceuticals To Start Phase 3 'REALIZE' Trial With Telaprevir In Treatment-Failure HCV Patients (Medical News Today)

Fri, 22 Aug 2008 07:00:00 GMT

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced that the Company has reached agreement with U.S. and E.U.

Source : Medical News Today (subscribe)

Explore : Health, NASDAQ

Vertex to Initiate Phase III Study of Hepatitis Drug (Red Orbit )

Wed, 20 Aug 2008 17:00:58 GMT

Vertex Pharmaceuticals has reached an agreement with the US and EU regulatory authorities to proceed with the Realize trial, a pivotal Phase III clinical trial with the hepatitis C virus protease inhibitor telaprevir in combination therapy for patients with chronic HCV infection who failed to achieve a sustained viral response with prior therapy.

Source : Red Orbit (subscribe)

Explore : Health

Vertex Pharmaceuticals to Start Phase 3 'REALIZE' Trial with Telaprevir in Treatment-Failure HCV Patients (Business Wire)

Tue, 19 Aug 2008 11:30:00 GMT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the Company has reached agreement

Source : Business Wire (subscribe)

Explore : Health Industries, NASDAQ

Vertex Pharmaceuticals Announces Webcast of its Presentation at the Canaccord Adams 28th Annual Global Growth Conference (Business Wire)

Fri, 08 Aug 2008 20:15:00 GMT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate

Source : Business Wire (subscribe)

Explore : Drug Manufacturers, Health Industries, NASDAQ

Vertex Pharmaceuticals cut to neutral at Susquehanna (Market Watch)

Wed, 06 Aug 2008 12:20:05 GMT

LONDON (MarketWatch) -- Susquehanna Financial downgraded Vertex Pharmaceuticals Inc. to neutral from positive, citing the Phase II trial results for Schering-Plough's boceprevir hepatitis C drug, which is a likely competitor to Vertex Pharma's telaprevir. The results could indicate that the efficacy advantage previously believed to be held by telaprevir will be diminished, Susquehanna said....

Source : Market Watch (subscribe)

Explore : Markets, Schering-Plough

Vertex Pharmaceuticals Announces Webcast of its Presentation at the 2008 BMO Capital Markets Focus on Healthcare Conference (Business Wire)

Tue, 05 Aug 2008 13:43:00 GMT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate

Source : Business Wire (subscribe)

Explore : Capital markets, Drug Manufacturers, Health Industries, Markets, NASDAQ

Vertex stock hurt by rival's news (The Boston Business Journal)

Mon, 04 Aug 2008 22:10:01 GMT

Great news from a rival hepatitis C drug developer helped drag down Vertex Pharmaceuticals Inc.’s stock more than 8.4 percent in trading late Monday. (SGP)

Source : The Boston Business Journal (subscribe)

Explore : Business

Schering-Plough drug results pressure Vertex stock (Reuters)

Mon, 04 Aug 2008 17:43:56 GMT

BOSTON (Reuters) - Schering-Plough Corp said on Monday that results from a study of its experimental hepatitis C drug showed promising results, sending the shares of rival Vertex Pharmaceuticals Inc down nearly 11 percent.

Source : Reuters (subscribe)

Explore : Business, Schering-Plough

Schering-Plough posts positive hep C data (Fiercebiotech)

Mon, 04 Aug 2008 16:12:20 GMT

Schering-Plough published promising new data for its experimental hepatitis C drug boceprevir, which pushed down the share value of rival Vertex Pharmaceuticals. After 48 weeks of therapy, researchers said, three out of every four patients receiving boceprevir in combination with standard therapy had undetectable levels of the virus. That compares to 38 percent with undetectable viral levels...

Source : Fiercebiotech (subscribe)

Explore : Schering-Plough

Vertex Pharmaceuticals Incorporated. Q2 2008 Earnings Call Transcript (Seeking Alpha)

Fri, 01 Aug 2008 03:00:35 GMT

Vertex Pharmaceuticals Incorporated (VRTX) Q2 2008 Earnings Call Complete Story »

Source : Seeking Alpha (subscribe)

Explore : China

Vertex Pharmaceuticals Highlights Telaprevir Progress and Reports Second Quarter 2008 Results (Red Orbit )

Thu, 31 Jul 2008 23:00:49 GMT

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported recent clinical progress and consolidated financial results for the quarter ended June 30, 2008.

Source : Red Orbit (subscribe)

Explore : Health, NASDAQ

Vertex Pharmaceuticals Highlights Telaprevir Progress and Reports Second Quarter 2008 Results (Business Wire)

Thu, 31 Jul 2008 20:17:00 GMT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported recent clinical progress and consolidated

Source : Business Wire (subscribe)

Explore : Health Industries, NASDAQ

Earnings Preview: Vertex Pharmaceuticals (Seeking Alpha)

Wed, 30 Jul 2008 18:30:18 GMT

Vertex Pharmaceuticals (VRTX) is expected to report Q2 earnings after market close Thursday, July 31, with a conference call scheduled July 31 for 5:00 p.m. ET. Guidance Analysts are looking for a loss of (60c) on revenue of $68.72M. The consensus range is (81c) to (41c) for EPS, and revenue of $38.56M to $87.23M, according to First Call. For Q1 the company reported EPS (72c) vs. consensus...

Source : Seeking Alpha (subscribe)

Explore : China

Vertex Pharmaceuticals Announces the Date of its Second Quarter 2008 Financial Results Conference Call and Webcast (Business Wire)

Thu, 17 Jul 2008 13:15:00 GMT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its second quarter 2008 financial results on Thursday, July 31, 2008 after the financial

Source : Business Wire (subscribe)

Explore : Drug Manufacturers, Health Industries, NASDAQ

Jim Greenwood, Josh Boger - BIO 2008 (IT Conversations)

Thu, 10 Jul 2008 05:00:00 GMT

On BioTech Nation, Dr. Moira Gunn speaks with BIO's Jim Greenwood, and Josh Boger from Vertex Pharmaceuticals during the anual International BIO Conference 2008.

Source : IT Conversations (subscribe)

ww.mac.ro News: Scientific Software Analyst - Silicon.com (mac.ro)

Sun, 22 Jun 2008 01:55:00 GMT

Tags: pharmaceuticals , scientists , chemistry , cambridge ma , preferable Scientific Software Analyst European Research Centre — Oxfordshire Vertex Pharmaceuticals Inc. is a global biotechnology company with research sites in Cambridge MA, La ...

Source : mac.ro (subscribe)

Explore : Biotechnology, Drug Manufacturers, Scientific Software, Software and services, Telecommunication

Vertex Establishes Early-Stage Huntington's Disease Research Collaboration with CHDI Foundation, Inc. (Business Wire)

Tue, 17 Jun 2008 07:01:00 GMT

SAN DIEGO--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated and CHDI Foundation, Inc. (CHDI) today announced a new collaboration aimed at developing assays for use in discovering novel

Source : Business Wire (subscribe)

Explore : Diseases, Health Industries

Vertex shares rise on positive data for telaprevir (Fiercebiotech)

Mon, 09 Jun 2008 15:52:41 GMT

Vertex Pharmaceuticals saw a significant bump in its share price this morning after researchers released new, mid-stage interim data backing telaprevir for hepatitis C. The company is now penciling Read more...

Source : Fiercebiotech (subscribe)

Explore : Drug Manufacturers

Vertex Reports 52% SVR 12 Rate for a 24-week Telaprevir-based Regimen in Genotype 1 Hepatitis C Patients Who Failed Prior Treatment (Business Wire)

Mon, 09 Jun 2008 11:30:00 GMT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from a planned

Source : Business Wire (subscribe)

Explore : Health Industries, NASDAQ

Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Johnson & Johnson, Schering Plough, Colgate-Palmolive and Procter & Gamble (Business Wire)

Mon, 09 Jun 2008 10:00:00 GMT

PermalinkTo save a permanent link to this news, right-click the date and time (Ctl-click on a Mac) and choose the command to copy the link, link location or shortcut.Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Johnson & Johnson, Schering Plough, Colgate-Palmolive and Procter & Gamble CHICAGO--()--Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks...

Source : Business Wire (subscribe)

Explore : Chemicals, Colgate-Palmolive, Conglomerates, Hygiene and Cosmetics, Procter & Gamble